AAPL344.59+5.09 (+1.50%) ▲|ABBV283.11-5.97 (-2.07%) ▼|ABT98.83-3.63 (-3.54%) ▼|ACN240.08+0.96 (+0.40%) ▲|ADBE255.87-0.86 (-0.34%) ▼|AMAT411.29+6.31 (+1.56%) ▲|AMD550.08+15.34 (+2.87%) ▲|AMGN435.60-3.34 (-0.76%) ▼|AMT179.03-4.53 (-2.47%) ▼|AMZN262.64+0.01 (+0.00%) ▲|AVGO337.09+2.72 (+0.81%) ▲|AXP323.91+5.57 (+1.75%) ▲|BA191.62+1.15 (+0.60%) ▲|BAC51.01+0.37 (+0.72%) ▲|BKNG157.98-5.94 (-3.62%) ▼|BLK1,136.54+7.86 (+0.70%) ▲|BMY60.84-0.85 (-1.37%) ▼|BNY146.34+2.09 (+1.45%) ▲|BRK-B542.91+3.09 (+0.57%) ▲|C123.25+0.74 (+0.60%) ▲|CAT736.22+10.98 (+1.51%) ▲|CL93.68-0.86 (-0.91%) ▼|CMCSA21.87-0.50 (-2.21%) ▼|COF209.61+8.05 (+3.99%) ▲|COP145.84-0.12 (-0.08%) ▼|COST995.37+0.76 (+0.08%) ▲|CRM242.91+0.48 (+0.20%) ▲|CSCO106.85+0.14 (+0.13%) ▲|CVS94.29-0.46 (-0.49%) ▼|CVX226.33+0.62 (+0.27%) ▲|DE631.14-1.07 (-0.17%) ▼|DHR232.70+8.46 (+3.77%) ▲|DIS110.84-0.83 (-0.74%) ▼|DUK121.43+0.10 (+0.08%) ▲|EMR163.27+2.81 (+1.75%) ▲|FDX298.99+0.23 (+0.08%) ▲|GD346.42+1.98 (+0.57%) ▲|GE300.83+0.96 (+0.32%) ▲|GEV928.69+38.36 (+4.31%) ▲|GILD152.93-3.59 (-2.29%) ▼|GM75.75-1.34 (-1.74%) ▼|GOOG328.98-7.42 (-2.21%) ▼|GOOGL332.99-7.29 (-2.14%) ▼|GS899.26+14.45 (+1.63%) ▲|HD314.35-0.76 (-0.24%) ▼|HON213.59+0.27 (+0.13%) ▲|IBM244.06+2.14 (+0.88%) ▲|INTC92.55+0.86 (+0.93%) ▲|INTU334.65-0.64 (-0.19%) ▼|ISRG431.71-6.30 (-1.44%) ▼|JNJ255.95-3.42 (-1.32%) ▼|JPM333.71-1.55 (-0.46%) ▼|KO92.91-0.58 (-0.62%) ▼|LIN499.54-2.35 (-0.47%) ▼|LLY1,268.01-15.65 (-1.22%) ▼|LMT549.58+0.87 (+0.16%) ▲|LOW196.58-0.71 (-0.36%) ▼|LRCX266.80+3.35 (+1.27%) ▲|MA623.27+2.85 (+0.46%) ▲|MCD245.81-0.71 (-0.29%) ▼|MDLZ62.81-1.18 (-1.84%) ▼|MDT93.51-1.13 (-1.19%) ▼|META710.75+16.50 (+2.38%) ▲|MMM171.12-0.25 (-0.15%) ▼|MO73.94-0.70 (-0.94%) ▼|MRK148.69+0.39 (+0.26%) ▲|MS183.57+3.17 (+1.76%) ▲|MSFT531.69-0.18 (-0.03%) ▼|MU912.63+16.56 (+1.85%) ▲|NEE78.59-0.27 (-0.35%) ▼|NFLX65.26-3.43 (-4.99%) ▼|NKE37.49-0.39 (-1.03%) ▼|NOW153.29+3.75 (+2.51%) ▲|NVDA220.46+3.99 (+1.84%) ▲|ORCL130.08-1.06 (-0.81%) ▼|PEP135.12+1.10 (+0.82%) ▲|PFE29.77-0.34 (-1.13%) ▼|PG157.75-1.58 (-0.99%) ▼|PLTR199.53+6.93 (+3.60%) ▲|PM196.75-3.15 (-1.58%) ▼|QCOM178.26+2.55 (+1.45%) ▲|RTX191.12-2.22 (-1.15%) ▼|SBUX98.82-0.55 (-0.55%) ▼|SCHW91.92+1.03 (+1.13%) ▲|SO90.71+0.00 (+0.00%) ▲|SPG206.31-0.68 (-0.33%) ▼|T21.98-1.45 (-6.17%) ▼|TMO702.36+14.99 (+2.18%) ▲|TMUS153.32-4.44 (-2.81%) ▼|TSLA386.40+12.69 (+3.40%) ▲|TXN286.26+8.48 (+3.05%) ▲|UBER68.18-0.76 (-1.10%) ▼|UNH416.31-2.96 (-0.70%) ▼|UNP289.75+2.14 (+0.74%) ▲|UPS99.61+1.09 (+1.10%) ▲|USB59.31+0.22 (+0.36%) ▲|V409.27+2.70 (+0.66%) ▲|VZ43.41-1.14 (-2.55%) ▼|WFC82.43+0.23 (+0.28%) ▲|WMT118.01+0.16 (+0.13%) ▲|XOM177.68-0.18 (-0.10%) ▼|AAPL344.59+5.09 (+1.50%) ▲|ABBV283.11-5.97 (-2.07%) ▼|ABT98.83-3.63 (-3.54%) ▼|ACN240.08+0.96 (+0.40%) ▲|ADBE255.87-0.86 (-0.34%) ▼|AMAT411.29+6.31 (+1.56%) ▲|AMD550.08+15.34 (+2.87%) ▲|AMGN435.60-3.34 (-0.76%) ▼|AMT179.03-4.53 (-2.47%) ▼|AMZN262.64+0.01 (+0.00%) ▲|AVGO337.09+2.72 (+0.81%) ▲|AXP323.91+5.57 (+1.75%) ▲|BA191.62+1.15 (+0.60%) ▲|BAC51.01+0.37 (+0.72%) ▲|BKNG157.98-5.94 (-3.62%) ▼|BLK1,136.54+7.86 (+0.70%) ▲|BMY60.84-0.85 (-1.37%) ▼|BNY146.34+2.09 (+1.45%) ▲|BRK-B542.91+3.09 (+0.57%) ▲|C123.25+0.74 (+0.60%) ▲|CAT736.22+10.98 (+1.51%) ▲|CL93.68-0.86 (-0.91%) ▼|CMCSA21.87-0.50 (-2.21%) ▼|COF209.61+8.05 (+3.99%) ▲|COP145.84-0.12 (-0.08%) ▼|COST995.37+0.76 (+0.08%) ▲|CRM242.91+0.48 (+0.20%) ▲|CSCO106.85+0.14 (+0.13%) ▲|CVS94.29-0.46 (-0.49%) ▼|CVX226.33+0.62 (+0.27%) ▲|DE631.14-1.07 (-0.17%) ▼|DHR232.70+8.46 (+3.77%) ▲|DIS110.84-0.83 (-0.74%) ▼|DUK121.43+0.10 (+0.08%) ▲|EMR163.27+2.81 (+1.75%) ▲|FDX298.99+0.23 (+0.08%) ▲|GD346.42+1.98 (+0.57%) ▲|GE300.83+0.96 (+0.32%) ▲|GEV928.69+38.36 (+4.31%) ▲|GILD152.93-3.59 (-2.29%) ▼|GM75.75-1.34 (-1.74%) ▼|GOOG328.98-7.42 (-2.21%) ▼|GOOGL332.99-7.29 (-2.14%) ▼|GS899.26+14.45 (+1.63%) ▲|HD314.35-0.76 (-0.24%) ▼|HON213.59+0.27 (+0.13%) ▲|IBM244.06+2.14 (+0.88%) ▲|INTC92.55+0.86 (+0.93%) ▲|INTU334.65-0.64 (-0.19%) ▼|ISRG431.71-6.30 (-1.44%) ▼|JNJ255.95-3.42 (-1.32%) ▼|JPM333.71-1.55 (-0.46%) ▼|KO92.91-0.58 (-0.62%) ▼|LIN499.54-2.35 (-0.47%) ▼|LLY1,268.01-15.65 (-1.22%) ▼|LMT549.58+0.87 (+0.16%) ▲|LOW196.58-0.71 (-0.36%) ▼|LRCX266.80+3.35 (+1.27%) ▲|MA623.27+2.85 (+0.46%) ▲|MCD245.81-0.71 (-0.29%) ▼|MDLZ62.81-1.18 (-1.84%) ▼|MDT93.51-1.13 (-1.19%) ▼|META710.75+16.50 (+2.38%) ▲|MMM171.12-0.25 (-0.15%) ▼|MO73.94-0.70 (-0.94%) ▼|MRK148.69+0.39 (+0.26%) ▲|MS183.57+3.17 (+1.76%) ▲|MSFT531.69-0.18 (-0.03%) ▼|MU912.63+16.56 (+1.85%) ▲|NEE78.59-0.27 (-0.35%) ▼|NFLX65.26-3.43 (-4.99%) ▼|NKE37.49-0.39 (-1.03%) ▼|NOW153.29+3.75 (+2.51%) ▲|NVDA220.46+3.99 (+1.84%) ▲|ORCL130.08-1.06 (-0.81%) ▼|PEP135.12+1.10 (+0.82%) ▲|PFE29.77-0.34 (-1.13%) ▼|PG157.75-1.58 (-0.99%) ▼|PLTR199.53+6.93 (+3.60%) ▲|PM196.75-3.15 (-1.58%) ▼|QCOM178.26+2.55 (+1.45%) ▲|RTX191.12-2.22 (-1.15%) ▼|SBUX98.82-0.55 (-0.55%) ▼|SCHW91.92+1.03 (+1.13%) ▲|SO90.71+0.00 (+0.00%) ▲|SPG206.31-0.68 (-0.33%) ▼|T21.98-1.45 (-6.17%) ▼|TMO702.36+14.99 (+2.18%) ▲|TMUS153.32-4.44 (-2.81%) ▼|TSLA386.40+12.69 (+3.40%) ▲|TXN286.26+8.48 (+3.05%) ▲|UBER68.18-0.76 (-1.10%) ▼|UNH416.31-2.96 (-0.70%) ▼|UNP289.75+2.14 (+0.74%) ▲|UPS99.61+1.09 (+1.10%) ▲|USB59.31+0.22 (+0.36%) ▲|V409.27+2.70 (+0.66%) ▲|VZ43.41-1.14 (-2.55%) ▼|WFC82.43+0.23 (+0.28%) ▲|WMT118.01+0.16 (+0.13%) ▲|XOM177.68-0.18 (-0.10%) ▼|
14.6 C
New York
Wednesday, October 21, 2026

Tag: therapies

newsFORsourcecompanycontentinformation1releasesmarket

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve...

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$439m

MELBOURNE, Australia, July 24, 2025 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million.

Citryll Announces Formation of Scientific Advisory Board

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD

Introducing Inner Harmony Spa Sg presenting Singapore’s best facials, massages, energy healing treatments in CBD

SINGAPORE, July 23, 2025 (GLOBE NEWSWIRE) -- Tucked away in the lively North Bridge district, Inner Harmony is a sanctuary of wellness—blending Asian traditions with European spa innovations to deliver transformative experiences. Whether one is seeking relaxation or rejuvenation, their comprehensive suite of services caters thoughtfully to every wellness need.

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company’s shares saw their investment crash over 60% that day.

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution...

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in...

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution...

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /CNW/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in...

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Conference Call and Webcast to Follow WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for...

Hydrasphere Plus Launches Comprehensive Skincare System Targeting Texture, Muscle Tone, and Collagen Renewal

Boca Raton, FL, July 23, 2025 (GLOBE NEWSWIRE) -- Hydrasphere Plus, a Florida-based skincare innovator, has officially launched a pioneering three-pillar system designed to transform the science of facial health. Built on decades of dermatological research and cosmetic formulation expertise, the new Hydrasphere Plus system uniquely targets skin texture, facial muscle tone, and collagen production—three biological pillars essential to long-term skin vitality.

CharacterStrong and Intellispark Partner to Deliver Integrated MTSS Platform that Will Change How Schools Support Student Mental Health

Collaboration includes strategic investment by CharacterStrong’s parent company FullBloom to further scale K-12 mental health solutions that improve student outcomes 
Collaboration includes strategic investment by CharacterStrong’s parent company FullBloom to further scale K-12 mental health solutions that improve student outcomes

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers